Together, this has led to an increase in the number of potential anorectic agents (e.g., analogues of PYY, GDF-15, Amylin, Amylin/Calcitonin dual agonists, etc.)under investigation for the treatment of obesity and T2D (44). This evidence concerns the gene IAPP and type 2 diabetes mellitus.